本文对来氟米特的作用机制、药动学及临床应用进行综述。
The mechanism, pharmacokinetic and clinical utilization of leflunomide are reviewed in this paper.
目的观察来氟米特联合乌蚌丸治疗类风湿关节炎的临床疗效。
Objective To observe the therapeutic effect of leflunomide tablets combined with Wubang pill on rheumatoid arthritis.
来氟米特的药物标签中有黑框警告：孕妇和准备要小孩的妇女禁用。
The drug label already features a boxed warning stating that leflunomide is contraindicated for pregnant women and for women of childbearing potential not using reliable contraception.
结论：生地马钱丸配合来氟米特治疗RA疗效优于单用来氟米特，且安全性好。
Conclusion: Habitat Strychnos pill with leflunomide for the treatment of RA is more effective than leflunomide alone, and the safety is good.
来氟米特通过随机双盲安慰剂对照试验研究表明，对强直性脊柱炎急性期没有效果。
Leflunomide was evaluated in a randomized, double-blind, placebo-controlled study in active ankylosing spondylitis but was not found to be effective.
结论来氟米特可显著改善BXSB小鼠的免疫状况和肾脏功能，能延缓BXSB狼疮鼠的疾病进程。
Conclusion Leflunomide can improve immune status and renal function of BXSB lupus mice, and delay their disease progression.
美国FDA今日宣布，治疗类风湿关节炎的药物来氟米特被给予黑框警告，因为它具有导致重度肝损伤的风险。
The rheumatoid arthritis drug leflunomide (Arava; sanofi-aventis) has received a boxed warning about the risk for severe liver injury, the US Food and Drug Administration (FDA) announced today.
目的观察来氟米特(LEF)与白芍总甙(TGP)治疗类风湿关节炎(RA)的临床疗效及实验室指标的变化。
ObjectiveThe observe the clinical effect of leflunomide (lef) and total glucosides of Paeony (TGP) on rheumatoid arthritis (ra) and their influences on laboratory findings.
怀孕前应终止使用的药物包括甲氨蝶呤、来氟米特和一些生物制剂包括抗肿瘤坏死因子制剂、利妥昔单抗和阿巴西普。
Drugs recommended to be stopped before pregnancy include methotrexate and leflunomide, plus the biologics: anti-TNF agents, rituximab and abatacept.
来氟米特或甲氨蝶呤单药治疗被推荐用于任何病程以及任何疾病活动度的患者的初始治疗，不论患者是否具有预后不良的特征表现。
Methotrexate or leflunomide monotherapy should be started for patients with all disease durations and for all degrees of disease activity irrespective of poor prognostic features.
通过近年某些国家对来氟米特副作用的论证，分析了可能对来氟米特的应用市场造成一定的影响，进而影响其中间体5 甲基异唑4 甲酰氯和对三氟甲基苯胺的市场。
Through the demonstration on side-effect of leflunomide made by some countries recently, the probable impact to application market of leflunomide and to its intermediates could be given.
通过近年某些国家对来氟米特副作用的论证，分析了可能对来氟米特的应用市场造成一定的影响，进而影响其中间体5 甲基异唑4 甲酰氯和对三氟甲基苯胺的市场。
Through the demonstration on side-effect of leflunomide made by some countries recently, the probable impact to application market of leflunomide and to its intermediates could be given.
应用推荐